The guideline is available at The guideline committee identified relevant review questions and collected and appraised clinical and cost effectiveness evidence
The efficacy of ABILIFY MAINTENA for the maintenance treatment of bipolar I disorder was established in a 52-week, double-blind, placebo-controlled, randomized withdrawal trial in adult patients who were experiencing a manic episode at trial entry, met DSM-IV-TR criteria for bipolar I disorder, and had a history of at least one previous manic or mixed episode with manic symptoms of sufficient severity to require one of the following interventions: hospitalization and/or treatment with a mood stabilizer, and/or treatment with an antipsychotic agent
Slowed digestion : Semaglutide also slows down how food leaves the digestive system
Gastrointestinal side effects: the common thread Nausea, diarrhea, vomiting, and constipation appear with all three medications
However, its legal compounding for patient use was prohibited under the 2023 Category 2 designation